Compare CBSH & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBSH | CYTK |
|---|---|---|
| Founded | 1865 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 7.6B |
| IPO Year | 2008 | 2004 |
| Metric | CBSH | CYTK |
|---|---|---|
| Price | $50.52 | $64.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 18 |
| Target Price | $59.22 | ★ $88.94 |
| AVG Volume (30 Days) | 985.1K | ★ 1.8M |
| Earning Date | 04-21-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.05% | N/A |
| EPS Growth | ★ 4.39 | N/A |
| EPS | ★ 4.04 | N/A |
| Revenue | N/A | ★ $13,368,000.00 |
| Revenue This Year | $17.20 | $6.88 |
| Revenue Next Year | $3.44 | $308.26 |
| P/E Ratio | $12.66 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $46.99 | $29.31 |
| 52 Week High | $66.31 | $70.98 |
| Indicator | CBSH | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 55.48 | 54.07 |
| Support Level | $46.99 | $59.12 |
| Resistance Level | $54.52 | $67.94 |
| Average True Range (ATR) | 0.90 | 2.25 |
| MACD | 0.44 | 0.26 |
| Stochastic Oscillator | 75.59 | 61.73 |
Commerce Bancshares Inc operates as the bank holding company for Commerce Bank. The bank is engaged in the general banking business, providing a broad range of retail, mortgage banking, corporate, investment, trust, and asset management products and services to individuals, businesses, and municipalities. It operates through three segments: Consumer, Commercial, and Wealth. The Commercial segment provides corporate lending, payment solutions, leasing, international services, and business banking. The Consumer segment covers retail banking, mortgages, installment lending, and card services. The Wealth segment offers trust and estate planning, brokerage, and investment management services.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.